AQR Capital Management LLC Has $10.81 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

AQR Capital Management LLC trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 25.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 121,249 shares of the medical equipment provider's stock after selling 42,168 shares during the quarter. AQR Capital Management LLC owned approximately 0.17% of Lantheus worth $10,807,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus in the third quarter worth about $25,000. Kestra Investment Management LLC bought a new position in Lantheus during the fourth quarter worth about $27,000. Summit Securities Group LLC bought a new position in Lantheus during the fourth quarter worth about $37,000. UMB Bank n.a. boosted its holdings in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC bought a new position in Lantheus during the third quarter worth about $60,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on LNTH shares. JMP Securities restated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Truist Financial reduced their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday. Finally, StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $132.67.

Lantheus Stock Up 1.8%

Shares of LNTH traded up $1.42 on Friday, hitting $81.86. The company's stock had a trading volume of 1,561,278 shares, compared to its average volume of 968,940. The firm's fifty day moving average price is $99.57 and its 200-day moving average price is $94.14. Lantheus Holdings, Inc. has a fifty-two week low of $75.00 and a fifty-two week high of $126.89. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 13.62 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the prior year, the firm posted $1.69 earnings per share. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 63,109 shares of company stock worth $6,016,046. 2.00% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.